Abstract

When clonidine (Catapres) and methyldopa (Aldomet, Dopamet, Medomet) were first introduced, they had advantages over other antihypertensive drugs then available. Now, however, their unwanted effects compare less favourably with those of newer antihypertensive regimens. Are they still needed at all?